SV2011003830A - Daa-piridina como ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes y para el tratamiento farmaceutico - Google Patents
Daa-piridina como ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes y para el tratamiento farmaceuticoInfo
- Publication number
- SV2011003830A SV2011003830A SV2011003830A SV2011003830A SV2011003830A SV 2011003830 A SV2011003830 A SV 2011003830A SV 2011003830 A SV2011003830 A SV 2011003830A SV 2011003830 A SV2011003830 A SV 2011003830A SV 2011003830 A SV2011003830 A SV 2011003830A
- Authority
- SV
- El Salvador
- Prior art keywords
- benzodiazepina
- piridina
- daa
- binding
- image diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nuclear Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPUESTOS NUEVOS ADECUADOS PARA MARCAR O YA MARCADOS CON 18F, CON MÉTODOS PARA PREPARAR TALES COMPUESTOS, CON COMPOSICIONES QUE COMPRENDEN DICHOS COMPUESTOS, CON CONJUNTOS DE ELEMENTOS QUE COMPRENDEN DICHOS COMPUESTOS O COMPOSICIONES Y CON LOS USOS DE DICHOS COMPUESTOS, COMPOSICIONES O CONJUNTOS DE ELEMENTOS EN TERAPIAS Y PARA DIAGNOSTICO POR IMÁGENES MEDIANTE TOMOGRAFIA DE EMISIÓN DE POSITRONES (PET)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08161903 | 2008-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2011003830A true SV2011003830A (es) | 2011-05-20 |
Family
ID=41198601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2011003830A SV2011003830A (es) | 2008-08-06 | 2011-02-04 | Daa-piridina como ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes y para el tratamiento farmaceutico |
Country Status (24)
Country | Link |
---|---|
US (1) | US20110200535A1 (es) |
EP (1) | EP2321279B1 (es) |
JP (1) | JP2011529929A (es) |
KR (1) | KR20110041559A (es) |
CN (1) | CN102112448B (es) |
AR (1) | AR073263A1 (es) |
AU (1) | AU2009278279B2 (es) |
BR (1) | BRPI0917099A2 (es) |
CA (1) | CA2733105A1 (es) |
CL (1) | CL2011000237A1 (es) |
CO (1) | CO6351715A2 (es) |
CR (1) | CR20110064A (es) |
DO (1) | DOP2011000046A (es) |
EA (1) | EA018650B1 (es) |
EC (1) | ECSP11010808A (es) |
IL (1) | IL210597A0 (es) |
MX (1) | MX2011001406A (es) |
NZ (1) | NZ590923A (es) |
PE (1) | PE20110226A1 (es) |
SV (1) | SV2011003830A (es) |
TW (1) | TW201010734A (es) |
UY (1) | UY32037A (es) |
WO (2) | WO2010015340A1 (es) |
ZA (1) | ZA201101700B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2474525B1 (en) | 2006-12-26 | 2020-04-15 | Lantheus Medical Imaging, Inc. | Ligands for imaging cardiac innervation |
WO2010015340A1 (en) * | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
GB0904715D0 (en) * | 2009-03-19 | 2009-05-06 | Ge Healthcare Ltd | Aryloxyanilide derivataives |
WO2011110488A1 (en) * | 2010-03-09 | 2011-09-15 | Bayer Pharma Aktiengesellschaft | A novel pet imaging agent of amyloid plaques and its precursor |
NZ604233A (en) | 2010-05-11 | 2014-10-31 | Lantheus Medical Imaging Inc | Compositions, methods and systems for the synthesis and use of imaging agents |
JP6022442B2 (ja) | 2010-05-14 | 2016-11-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 男性用避妊組成物および使用方法 |
MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
AU2011252808B2 (en) | 2010-05-14 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
ES2731471T3 (es) | 2011-09-09 | 2019-11-15 | Lantheus Medical Imaging Inc | Composiciones, métodos y sistemas para la síntesis y el uso de agentes de obtención de imágenes |
BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
KR20160115953A (ko) | 2014-01-31 | 2016-10-06 | 다나-파버 캔서 인스티튜트 인크. | 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도 |
WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
RU2722179C2 (ru) | 2014-02-28 | 2020-05-28 | Тэнша Терапеутикс, Инк. | Лечение состояний, ассоциированных с гиперинсулинемией |
MX2017001756A (es) | 2014-08-08 | 2017-05-30 | Dana Farber Cancer Inst Inc | Derivados de diazepano y sus usos. |
MX2017001757A (es) | 2014-08-08 | 2017-05-30 | Dana Farber Cancer Inst Inc | Derivados de dihidropteridinona y sus usos. |
EP3212654B1 (en) | 2014-10-27 | 2020-04-08 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
UA123946C2 (uk) | 2015-09-11 | 2021-06-30 | Дана-Фарбер Кенсер Інстітьют, Інк. | Ацетамідтієнотриазолодіазепіни й шляхи їх застосування |
RU2750164C2 (ru) | 2015-09-11 | 2021-06-22 | Дана-Фарбер Кэнсер Инститьют, Инк. | Цианотиенотриазолодиазепины и пути их применения |
WO2017091673A2 (en) | 2015-11-25 | 2017-06-01 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibtors and uses thereof |
CN105541931B (zh) * | 2016-01-07 | 2018-08-17 | 江西师范大学 | 一种氟代糖苷衍生物及其制备方法 |
EA202091323A1 (ru) * | 2017-12-01 | 2020-10-09 | Юсб Байофарма Срл | Визуализирующие средства |
CN111039853B (zh) * | 2019-12-26 | 2023-02-14 | 安徽大学 | 一种可用于光声成像和光热治疗的铁配合物及其制备方法和用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2186186T3 (es) * | 1997-08-04 | 2003-05-01 | Taisho Pharmaceutical Co Ltd | Derivados ariloxianilina. |
JP2000001476A (ja) * | 1998-06-15 | 2000-01-07 | Taisho Pharmaceut Co Ltd | アリールオキシ含窒素アリールアミン誘導体 |
JP2004231647A (ja) * | 2003-01-10 | 2004-08-19 | Natl Inst Of Radiological Sciences | フェニルオキシアニリン誘導体 |
US6870069B2 (en) * | 2003-01-10 | 2005-03-22 | National Institute Of Radiological Sciences | Phenyloxyaniline derivatives |
GB0329716D0 (en) * | 2003-12-23 | 2004-01-28 | Amersham Plc | Radical trap |
GB0407952D0 (en) * | 2004-04-08 | 2004-05-12 | Amersham Plc | Fluoridation method |
US8644910B2 (en) * | 2005-07-19 | 2014-02-04 | Biosensors International Group, Ltd. | Imaging protocols |
DE102005055524B4 (de) * | 2005-11-22 | 2013-02-07 | BEGO Bremer Goldschlägerei Wilh. Herbst GmbH & Co. KG | Verfahren, Vorrichtung und System zur Herstellung eines keramischen Formkörpers |
US20080293969A1 (en) * | 2005-11-22 | 2008-11-27 | Ge Healthcare Limited | 18F-Labeled Daa Analogues and Method of Labeling These Analogues as Positron Emission Tomography (Pet) Tracers For Imaging Peripheral Benzodiazepine Receptors |
GB0525949D0 (en) * | 2005-12-21 | 2006-02-01 | Hammersmith Imanet Ltd | Pet radiotracers |
MX2008016344A (es) * | 2006-06-21 | 2009-02-12 | Ge Healthcare Ltd | Productos radiofarmaceuticos. |
WO2010015340A1 (en) * | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
-
2009
- 2009-07-25 WO PCT/EP2009/005399 patent/WO2010015340A1/en active Application Filing
- 2009-08-03 TW TW098126076A patent/TW201010734A/zh unknown
- 2009-08-05 WO PCT/EP2009/005651 patent/WO2010015387A1/en active Application Filing
- 2009-08-05 CN CN200980130507.6A patent/CN102112448B/zh not_active Expired - Fee Related
- 2009-08-05 NZ NZ590923A patent/NZ590923A/xx not_active IP Right Cessation
- 2009-08-05 MX MX2011001406A patent/MX2011001406A/es not_active Application Discontinuation
- 2009-08-05 UY UY0001032037A patent/UY32037A/es not_active Application Discontinuation
- 2009-08-05 US US13/057,215 patent/US20110200535A1/en not_active Abandoned
- 2009-08-05 EA EA201100301A patent/EA018650B1/ru not_active IP Right Cessation
- 2009-08-05 BR BRPI0917099A patent/BRPI0917099A2/pt not_active IP Right Cessation
- 2009-08-05 JP JP2011521474A patent/JP2011529929A/ja active Pending
- 2009-08-05 KR KR1020117005160A patent/KR20110041559A/ko not_active Application Discontinuation
- 2009-08-05 CA CA2733105A patent/CA2733105A1/en not_active Abandoned
- 2009-08-05 AU AU2009278279A patent/AU2009278279B2/en not_active Ceased
- 2009-08-05 AR ARP090102997A patent/AR073263A1/es not_active Application Discontinuation
- 2009-08-05 EP EP09777654.6A patent/EP2321279B1/en not_active Not-in-force
- 2009-08-05 PE PE2011000123A patent/PE20110226A1/es not_active Application Discontinuation
-
2011
- 2011-01-12 IL IL210597A patent/IL210597A0/en unknown
- 2011-02-04 SV SV2011003830A patent/SV2011003830A/es not_active Application Discontinuation
- 2011-02-04 EC EC2011010808A patent/ECSP11010808A/es unknown
- 2011-02-04 CO CO11013225A patent/CO6351715A2/es not_active Application Discontinuation
- 2011-02-04 CL CL2011000237A patent/CL2011000237A1/es unknown
- 2011-02-04 DO DO2011000046A patent/DOP2011000046A/es unknown
- 2011-02-04 CR CR20110064A patent/CR20110064A/es unknown
- 2011-03-04 ZA ZA2011/01700A patent/ZA201101700B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201101700B (en) | 2014-08-27 |
MX2011001406A (es) | 2011-03-21 |
EP2321279B1 (en) | 2014-07-02 |
AU2009278279B2 (en) | 2014-04-17 |
US20110200535A1 (en) | 2011-08-18 |
IL210597A0 (en) | 2011-03-31 |
JP2011529929A (ja) | 2011-12-15 |
CA2733105A1 (en) | 2010-02-11 |
CO6351715A2 (es) | 2011-12-20 |
DOP2011000046A (es) | 2011-02-28 |
CN102112448B (zh) | 2014-08-06 |
EP2321279A1 (en) | 2011-05-18 |
CN102112448A (zh) | 2011-06-29 |
WO2010015387A1 (en) | 2010-02-11 |
TW201010734A (en) | 2010-03-16 |
CL2011000237A1 (es) | 2011-07-29 |
NZ590923A (en) | 2012-12-21 |
UY32037A (es) | 2010-03-26 |
EA018650B1 (ru) | 2013-09-30 |
ECSP11010808A (es) | 2011-03-31 |
AR073263A1 (es) | 2010-10-28 |
CR20110064A (es) | 2011-03-30 |
WO2010015340A1 (en) | 2010-02-11 |
KR20110041559A (ko) | 2011-04-21 |
BRPI0917099A2 (pt) | 2016-02-16 |
EA201100301A1 (ru) | 2011-12-30 |
PE20110226A1 (es) | 2011-04-01 |
AU2009278279A1 (en) | 2010-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2011003830A (es) | Daa-piridina como ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes y para el tratamiento farmaceutico | |
UY32923A (es) | Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
GT201200147A (es) | Antagonistas de espiro-oxindol de mdm2 | |
ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
AR092177A1 (es) | Metodos para tratar o prevenir asma administrando un antagonista de il-4r | |
CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
CL2011002255A1 (es) | Compuestos derivados de 2-acetamino-5-aril-(1,2,4-triazolona o imidazolona), antagonista del receptor v1a y v2; composicion farmaceutica que los comprende; procedimiento de preparacion; y su uso en el tratamiento de insuficiencia cardiaca, hiponatremia hipervolemica y euvolemica, ascitis, ademas, entre otras. | |
CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
CL2014000225A1 (es) | Compuestos derivados de 1,2,4-triazol; composicion farmaceutica; procedimiento de preparacion de procursores de los mismos y el uso como moduladores del transporte nuclear en el tratamiento de enfermedades tales como cancer. | |
CR20150326A (es) | Inhibidores de autotaxina | |
CO6721010A2 (es) | Antagonistas de mdm2 de espiro-oxindol | |
CO6551740A2 (es) | Derivados pirazólicos como moduladores de los canales de calcio activados por la liberación de calcio | |
CL2013002517A1 (es) | Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer. | |
CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
CL2008001335A1 (es) | Compuestos derivados de pirrolopirimidin-7-ona, antagonistas de los receptores de purina p2x; porceso de preparacion de estos; composicion farmaceutica que los comprende; proceso de preparacion de compuestos intermediarios y usos en el tratamientos del dolor, vejiga hiperactiva, entre otras. | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
CO6400170A2 (es) | Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos | |
HN2010002030A (es) | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 | |
ECSP13012368A (es) | Composiciones farmacéuticas de co-cristales de tramadol y coxibs | |
CL2012001322A1 (es) | Compuestos derivados de piridinopiridinona, inhibidores pdgf; procedimiento de preparacion de estos; composición farmacéutica que los comprende; combinación farmacéutica; y su uso en el tratamiento del cancer, ateroesclerosis, enfermedades cardiacas, diabetes, renales, entre otras. | |
UY32734A (es) | Compuestos agonistas del receptor esfingosina 1-fosfato |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Lapse |